Published in Women's Health Weekly, November 26th, 2009
"Our alliances have continued to achieve strong progress with Roche's initiation of the Phase 3 registration trial for subcutaneous Herceptin, and Baxter's completion of patient enrollment in the Phase 3 GAMMAGARD with PH20 pivotal study and the launch of Hylenex in pediatric hydration," said Jonathan Lim, M.D., president and CEO. "Our balanced business strategy consisting...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly